Methods and compositions for improving sleep

• US 20020015740A1
• Filed: 02/22/2001
• Published: 02/07/2002
• Est. Priority Date: 02/22/2000
• Status: Active Grant

• Current Assignee: Queen's University At Kingston
• Original Assignee: Cellegy Canada Incorporated
• Inventors: Adams, Michael A., Heaton, Jeremy P.W., Ackman, C. Bruce, Ratz, Jodan D.
• Granted Patent: US 6,586,478 B2
• Time in Patent Office: Days
• US Class Current: 424/600
• CPC Class Codes: A61K 31/21 Esters, e.g. nitroglycerine, selenocyanates
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives

Abstract

Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.

Claims

1. A method for improving sleep in an individual suffering from a sleep disorder or a condition wherein normal sleep is interrupted or interfered with, said method comprising administering to the individual a NO-mimetic in an amount therapeutically effective to improve sleep in the individual.

2. The method of claim 1 wherein the amount of NO-mimetic administered is less than an amount effective to appreciably alter systemic vascular tone.

3. The method of claim 2 where the amount of NO-mimetic administered is one half to one fortieth of the amount of NO-mimetic known to appreciably alter systemic vascular tone in normal circulation in a human.

4. The method of claim 1, wherein the NO-mimetic is administered by transdermal patch.

5. The method of claim 1 wherein the NO-mimetic is co-administered with an established drug for sleep disorders or a condition wherein normal sleep is interrupted or interfered with.

6. A method for decreasing a therapeutic dosage of an established drug for sleep disorders or a condition wherein normal sleep is interrupted or interfered with, said method comprising co-administering the established drug with a NO-mimetic.

7. A pharmaceutical composition comprising a NO-mimetic and an established drug for sleep disorders or a condition wherein normal sleep is interrupted or interfered with.